Semaglutide 2.4 mg for Weight Loss: What the Evidence Actually Shows

What the trial data at 2.4 mg actually showed

The STEP 1 trial enrolled 1,961 adults with obesity or overweight plus at least one weight-related condition, all without type 2 diabetes. Those assigned to semaglutide 2.4 mg lost an average of 14.9% of body weight at 68 weeks; participants who adhered fully to treatment saw even greater reductions. More than two-thirds of those on the active dose lost at least 10% of body weight, and around one in three lost 20% or more. These results were achieved alongside a reduced-calorie diet and increased physical activity, which reflects how the treatment is intended to be used in practice.

NICE cited this evidence when recommending semaglutide for weight management in adults, setting out eligibility criteria in technology appraisal TA875. The ~15% average is a population figure. Individual outcomes vary considerably depending on starting weight, how long treatment continues, diet quality, and how well the dose is tolerated. The 2.4 mg dose is not a starting point, it is where the titration schedule is designed to arrive, usually after around five months of gradual increases from 0.25 mg. If you want to understand how dose progression is structured across the full schedule, the Wegovy dosing guide sets this out clearly.

A newer, higher maintenance dose of 7.2 mg was approved by the MHRA in January 2026 and is now available as a dedicated single-dose pen, with trials reporting around 20.7% average weight loss at 72 weeks, and you can read more about what semaglutide 7 mg means for weight loss outcomes if that higher dose is something you want to explore. That context is worth knowing, though for most people the journey still begins with the same titration that leads to 2.4 mg first.

How 2.4 mg semaglutide works on appetite and weight

Semaglutide is a GLP-1 receptor agonist, it mimics a gut hormone released naturally after eating. At the 2.4 mg maintenance dose, it acts on receptors in the brain's appetite-regulating centres and slows the rate at which the stomach empties. The combined effect is that hunger signals are quieter and meals feel satisfying sooner. Many people describe eating less without consciously restricting themselves; portion sizes that previously felt inadequate become sufficient.

This mechanism is meaningfully different from willpower or habit alone. Weight is shaped by biology, and GLP-1 pathways are part of that biology. Semaglutide doesn't override the system, it works within it. For a broader look at where semaglutide sits within the wider range of licensed weight-loss options, the weight management treatment overview covers the landscape.

The NHS medicines page for semaglutide provides a patient-level explanation of how it works and what to expect from treatment. It's a useful read before or alongside a clinical consultation, though specific dosing decisions always rest with the prescriber reviewing your individual case.

Side effects to be aware of at this dose

The most commonly reported side effects with semaglutide 2.4 mg are gastrointestinal: nausea, loose stools, constipation, indigestion, and occasional vomiting. In the STEP 1 trial, around 44% of participants in the semaglutide group reported nausea at some point, compared with around 16% on placebo. That sounds significant, but most cases were mild to moderate and settled as the body adjusted, usually within the first couple of weeks at each new dose level.

The gradual titration from 0.25 mg upwards exists largely to reduce the intensity of these early symptoms. Fatigue, headache, and dizziness are also reported, particularly early in treatment. Rare but serious risks include pancreatitis (seek urgent medical attention for severe stomach pain that radiates to the back) and gallbladder problems. Any suspected side effect can be reported through the MHRA Yellow Card scheme. The prescriber reviewing your case will discuss contraindications and individual risk factors before treatment begins, this page covers the general picture, not personal medical advice.

One thing our prescribers hear regularly: people are surprised that the nausea at 2.4 mg is often no worse than it was at earlier dose steps, because the titration has already given the body time to adapt. The final step up is usually the smoothest. For more detail on what to expect dose by dose, the 2.4 mg Wegovy page goes deeper on practical experience at this maintenance level.

Who can access semaglutide 2.4 mg, and what to consider before starting

The licensed eligibility criteria for semaglutide 2.4 mg (Wegovy) are: adults with a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. These are the licence criteria; a prescriber also considers the full clinical picture, including any contraindications, existing medicines, and relevant health history.

NHS access to Wegovy remains limited, primarily through specialist weight management services under NICE TA875 and with significant waiting times in most areas. Privately, a regulated online pharmacy can offer a faster route, provided the clinical assessment is genuine and thorough. The Wegovy cost guide covers what private treatment typically involves financially, because price context is part of making an informed decision. Treatment is not recommended during pregnancy, while breastfeeding, or when trying to conceive; it is not licensed for under-18s.

If you've been reading about the full titration schedule and wondering how the earlier steps compare, our guide to what semaglutide 1 mg delivers for weight loss is a good reference point for understanding how results build across the schedule before you reach the maintenance dose. If you'd like to understand what the semaglutide 2 mg dose means for weight loss as an intermediate step on that journey, that page walks through what to expect at that stage. When you're ready to talk to a prescriber directly, you can start a free consultation with the nume team. Every application is reviewed by a GPhC-registered Independent Prescriber on the same day it's submitted.